about
Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo, TanzaniaImpact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in ZanzibarEfficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategiesA phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsEfficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trialSafety and immunogenicity of RTS,S/AS02D malaria vaccine in infantsPrevalence of malaria parasitemia and purchase of artemisinin-based combination therapies (ACTs) among drug shop clients in two regions in Tanzania with ACT subsidiesIntermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: a multicentre randomized controlled trialIntermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trialEconomic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancyMortality, Morbidity, and Developmental Outcomes in Infants Born to Women Who Received Either Mefloquine or Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy: A Cohort StudyMulti-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with ElectrocardiogramsVirosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & childrenEfficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Relationship between child survival and malaria transmission: an analysis of the malaria transmission intensity and mortality burden across Africa (MTIMBA) project data in Rufiji demographic surveillance system, Tanzania.Modelling heterogeneity in malaria transmission using large sparse spatio-temporal entomological data.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialBaseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.Preventing childhood malaria in Africa by protecting adults from mosquitoes with insecticide-treated nets.A nationwide survey of the quality of antimalarials in retail outlets in TanzaniaSafety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients.The contribution of reduction in malaria as a cause of rapid decline of under-five mortality: evidence from the Rufiji Health and Demographic Surveillance System (HDSS) in rural TanzaniaCommunity-Associated Staphylococcus aureus from Sub-Saharan Africa and Germany: A Cross-Sectional Geographic Correlation StudySafety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohortImproved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites.Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.Medication exposure during pregnancy: a pilot pharmacovigilance system using health and demographic surveillance platform.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam.Enterobiasis and strongyloidiasis and associated co-infections and morbidity markers in infants, preschool- and school-aged children from rural coastal Tanzania: a cross-sectional studyThe effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsPharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malariaDistribution and risk factors for Plasmodium and helminth co-infections: a cross-sectional survey among children in Bagamoyo district, coastal region of Tanzania.Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and TanzaniaPlasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.
P50
Q21245521-26E1ABB0-DF11-4177-944F-386FA727B31CQ22061782-E49DD48B-7D08-4235-B965-AA74033D00B7Q24812384-1B94BA77-2D14-4A77-831E-EBBE144234A5Q28278852-382A98B3-D4A0-48BE-B68C-636D59045CD6Q28297711-AA87E106-FEC8-4DFD-97ED-E332CCD41BB0Q28303270-B8B856B2-4D4D-4B11-B18D-EAD4938FB82DQ28537811-8E57A35D-7224-45E0-AE1A-FE78677B9326Q28543146-3814A273-DF05-4EF2-AF71-480FE74F223AQ28543154-CF2D0F93-6B2C-461A-A26C-799C4B3957CFQ28546725-F35437DD-540C-4338-90B1-717449C27D4FQ28550346-72A08B75-EB76-46C7-B228-2A2196A09F04Q28552793-BF5AB8B0-D4A2-4269-BBAD-4BEAAC3B11B9Q28742277-63F65968-C513-4062-A368-B7CF3E42B0BCQ30596414-A29DD6E7-26C6-43B3-AD13-5479CE170DFBQ30788258-FB4566F3-EC72-48B9-AC11-58DBA170773FQ30833356-9C98B191-9063-40A1-8521-D53180614820Q30991737-A21DB1DA-3F38-4FBD-895C-69A4133E67C2Q30995133-E7D17B60-6AE3-4C49-808F-5F1D2775131FQ33289778-8EC88247-46DC-4551-A1F3-79FF4B38505FQ33377031-37A8F33C-F4DD-4600-A9BF-F672B70CC78BQ33640455-C2994B50-4DCD-44B6-9BBF-C8B59974BC03Q33645746-224625C0-279E-4E88-A9C3-E72272FCF27DQ33670238-C48C142A-06E6-4A3D-89F6-2D6E7659C5D8Q33693707-E5F77D7F-4BCB-46BD-8C64-355DCF7E7A02Q33876965-AE0723A7-B0B1-4F2D-8B7F-23454DD908F2Q34014169-4A9A5BAD-67D8-4A66-A25A-20549453E706Q34058351-3C265D3F-9FE2-4791-B87F-B387DE88C7EBQ34138437-06407DA4-A793-4837-8673-5C50B62BDAA3Q34202910-8E32567A-646D-43E6-AF15-DC948203ADB1Q34253760-CB4C0BE8-46F0-46E6-BC56-DE5EFFBAAD55Q34487139-9FC7181C-EC96-4C44-866A-22189D5136F4Q34557276-E9ACE413-1532-4BEA-8779-27D3457CD713Q34739932-EDFA3B7F-6CA0-48D5-AF1C-0A23EE8E473AQ35105075-85008569-77D1-400A-9A7F-19247F5F25E1Q35191375-8FCF611C-46C1-42C7-A700-37414AC9F655Q35251077-430DDC8F-D5DE-48A7-81BB-45ABFD8E2C09Q35428630-520EAA7D-0751-415A-91AB-141DF18045C1Q35439859-0FE2504F-7549-4A0D-9221-27E40DC50F7AQ35519260-AD782211-7F37-40A5-B36D-4AC2A1A8F310Q35761064-42D93F87-BED4-4986-A478-BEDC56CF884F
P50
name
Salim Abdulla
@en
Salim Abdulla
@nl
type
label
Salim Abdulla
@en
Salim Abdulla
@nl
prefLabel
Salim Abdulla
@en
Salim Abdulla
@nl